Nov 01,2016

Tandem Diabetes Care Reports Third Quarter 2016 Financial Results

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported its financial results for the quarter ended September 30, 2016 and updated its financial guidance for the year ending December 31, 2016. Pump shipments grew 14 percent to 3,896 for the third quarter of 2016 compared to 3,431 pumps shipped in the same period of 2015. However, GAAP sales declined 22 percent to $12.3 million for the quarter ended September 30, 2016 compared to $15.7 million for the same period of 2015.

View Analyst & Ambassador Comments
Go to original news
Nov 02,2016

New Study Shows Majority of Omnipod® Insulin Management System Users Report Significant Clinical and Quality of Life Benefits

Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced the online publication of new data in Diabetes Technology & Therapeutics1 that continue to validate the substantial quality of life benefits of the Omnipod System. In this study, more than 1,200 current adult Omnipod users with type 1 diabetes completed an online questionnaire to examine perceived changes in quality of life and glycemic control. The majority reported positive changes in perceived control over their diabetes (72.5%), diabetes distress (69.6%), overall well-being (53.5%) and hypoglycemic safety (50.6%) since starting use of Omnipod (P < 0.001).

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Nov 03,2016

Insulet Reports Third Quarter 2016 Financial Results

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months ended September 30, 2016. Third quarter 2016 revenue increased 33% to $94.9 million, compared to revenue from continuing operations of $71.4 million in the third quarter of 2015.

View Analyst & Ambassador Comments
Go to original news
Nov 03,2016

Senseonics Holdings, Inc. Reports Third Quarter 2016 Financial Results

Senseonics Holdings, Inc. (NYSE-MKT: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the third quarter and nine months ended September 30, 2016. Net loss was $10.9 million, or $0.12 per share, in the third quarter of 2016, compared to $8.6 million, or $4.39 per share, in the third quarter of 2015.

View Analyst & Ambassador Comments
Go to original news
Nov 04,2016

Insulet to Webcast Investor Day on November 16, 2016

Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced it will host an Investor Day on November 16, 2016, in Boston, Massachusetts. The presentation will begin at 10:30 a.m. (Eastern Time) followed by a question and answer session, and is expected to end at 2:00 p.m., with product exhibits to follow. The day will end at 3:00 p.m. The presentation will be webcast live and may be accessed via Insulet's website at http://investors.insulet.com under the Investor Relations section. Materials accompanying the presentation will also be posted within this section under "Events and Presentations" following the event.

View Analyst & Ambassador Comments
Go to original news
Nov 07,2016

DarioHealth to Host Third Quarter 2016 Conference Call on November 11, 2016

DarioHealth Corp. (NASDAQ: DRIO), a leader in digital health and mobile health solutions and the developer of the Dario™ Blood Glucose Monitoring System, an all-in-one diabetes meter, announced today that it will release its third quarter 2016 results on Thursday, November 10 and host a third quarter 2016 earnings and business update at 9:00am EST on Friday, November 11.

View Analyst & Ambassador Comments
Go to original news
Nov 10,2016

DarioHealth Reports Third Quarter 2016 Results

DarioHealth Corp. (NASDAQ: DRIO), developer of the Dario™ Blood Glucose Monitoring System, today reported financial and operational results for the three and nine month periods ended September 30, 2016. Revenue for the third quarter of 2016 was $728,000, a 166% increase from $273,000 in third quarter of 2015 and a 9% increase sequentially from the second quarter of 2016.

View Analyst & Ambassador Comments
Go to original news
Nov 10,2016

BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced a new research collaboration supported by JDRF, the leading global organization funding type 1 diabetes (T1D) research. The collaboration expands the commitment from JDRF and BD to explore new advancements in therapy options for people with type 1 diabetes. This new, two-year funding commitment from JDRF will enable BD to focus on technology enhancements to support the development of an extended wear insulin infusion set.

COLLABORATION PARTNERSHIP

#institution

View Analyst & Ambassador Comments
Go to original news
Nov 10,2016

NIH-funded International Diabetes Closed Loop (IDCL) Trial to Combine Technologies from Tandem Diabetes Care, Dexcom and TypeZero

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, Dexcom, Inc. (NASDAQ: DXCM), a leader in continuous glucose monitoring (CGM) for people with diabetes, and TypeZero Technologies, LLC, a digital health and personalized medicine company, today announced that they are working together on the integration of their technologies into the NIH-funded International Diabetes Closed Loop (IDCL) Trial starting later this year.

COLLABORATION PARTNERSHIP

#r&d

#closed loop

View Analyst & Ambassador Comments
Go to original news
Nov 11,2016

Presentation of PRECISE II U.S. Pivotal Trial Data of the Eversense CGM System at the 16th Annual Diabetes Technology Meeting

Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, presented results of the PRECISE II U.S. pivotal trial at this week’s 16th Annual Diabetes Technology Meeting in Bethesda, Maryland. Study results show 93% of readings were within 20% of the YSI reference. The detection rate at the hypoglycemia alert setting (70 mg/dL) was 93% and 96% at the hyperglycemia alert setting (180 mg/dL).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES